Login to Your Account

Clinic Roundup

Wednesday, December 7, 2011
• Isis Pharmaceuticals Inc., of Carlsbad, Calif., reported Phase I results showing that its ISIS-APOCIIIRx treatment produced rapid, dose-dependent reductions of up to 78 percent in apolipoprotein C-III protein and up to 44 percent in blood triglyceride levels in healthy volunteers. The drug, which targets the apoC-III gene, also was found to be safe and well tolerated. Data were presented at the Cold Spring Harbor Laboratory RNA Therapeutics meeting in New York.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription